Abstract
Background: Pancreatic cancer (PC) is a malignant tumor with hidden incidence, high degree of malignancy, rapid disease progression, and poor prognosis. Eukaryotic translation initiation factor 3 subunit B (EIF3B) is necessary for tumor growth, which is an alternative therapeutic target for many cancers. However, little is known about the relationship between EIF3B and PC.Methods: The expression of EIF3B in PC was detected by immunohistochemistry. EIF3B knockdown cell models were constructed by lentivirus infection. The MTT assay, the wound-healing assay, the transwell assay, the flow cytometry, and the Human Apoptosis Antibody Array was used to detect the effects of EIF3B knockdown on cell proliferation, cell migration, cell apoptosis, and cell cycle in vitro. Also, the effects of EIF3B knockdown on the tumor growth of PC were determined in vivo.Results: This study showed that the expression level of EIF3B was significantly up-regulated in PC tumor tissues and associated with pathological grade. In vitro, EIF3B knockdown inhibited the PC cell proliferation and migration, and the apoptosis levels were obviously promoted by regulating apoptosis-related proteins including Bcl-2, HSP27, HSP60, Survivin, sTNF-R2, TNF-α, TNF-β, TRAILR-3, TRAILR-4, and XIAP. Furthermore, the tumor growth of PC was inhibited after the knockdown of EIF3B in vivo.Conclusion: EIF3B was up-regulated in PC and was a promoter in the development and progression of PC, which could be considered as a therapeutic target for the treatment of PC.
Highlights
Pancreatic cancer (PC) is a malignant tumor of the digestive system, which has the characteristics of hidden incidence, high degree of malignancy, rapid disease progression, poor prognosis, and high mortality rate [1, 2]
The expression levels of Eukaryotic translation initiation factor 3 subunit B (EIF3B) in PC tumor tissues and paracarcinoma tissues were determined by immunohistochemical staining
It was obvious that EIF3B expression was significantly up-regulated in tumor tissues compared with para-carcinoma tissues (Figure 1A), which was indicated by the statistical analysis (P < 0.001, Table 1)
Summary
Pancreatic cancer (PC) is a malignant tumor of the digestive system, which has the characteristics of hidden incidence, high degree of malignancy, rapid disease progression, poor prognosis, and high mortality rate [1, 2]. The sectional progression and the tolerances to radiotherapy and chemotherapy occur in some patients after the treatment [4]. With the progress of PC research and the continuous improvement of treatment methods, more new potential therapeutic targets have been discovered, and clinical application of a variety of specific therapeutic target inhibitors has achieved certain results [7, 8]. Some therapeutic target inhibitors in a clinical test did not obtain satisfactory results. Pancreatic cancer (PC) is a malignant tumor with hidden incidence, high degree of malignancy, rapid disease progression, and poor prognosis. Little is known about the relationship between EIF3B and PC
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
